ReviewPharmacology research & perspectives2021
Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.
Review in Pharmacology research & perspectives, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 40 citations in OpenAlex.
- A Systematic Review and Meta-Analysis of Doxazosin Pharmacokinetics in Healthy and Diseased Populations.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Navigating Drug-Drug Interactions in Multimorbid Patients: Utilizing Tools, Guidelines, and Clinical Implications.Current drug safety · 2025Article
- Article
- Prevalence of Potential Drug-drug Interactions With Ritonavir-containing COVID-19 Therapy in the United States: An Analysis of the National Health and Nutrition Examination Survey.Clinical therapeutics · 2023Article
- COVID-19-Associated Acute Psychotic Disorder-Longitudinal Case Report and Brief Review of Literature.Medicina (Kaunas, Lithuania) · 2023Review
- Prevalence of COVID-19 outcomes in patients referred to opioid agonist treatment centers.Frontiers in pharmacology · 2023Article
- Drug-Drug Interactions among Patients Hospitalized with COVID-19 in Greece.Journal of clinical medicine · 2022Article
- Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients.African health sciences · 2022Article
- A New Chemometrically Assisted UV Spectrophotometric Method for Simultaneous Determination of Tamsulosin and Dutasteride in Their Pharmaceutical Mixture.Journal of AOAC International · 2022Article
- Review
- In vitro evaluation of the impact of Covid-19 therapeutic agents on the hydrolysis of the antiviral prodrug remdesivir.Chemico-biological interactions · 2022Article
- Can anti-parasitic drugs help control COVID-19?Future virology · 2022Review
- Molnupiravir: A new candidate for COVID-19 treatment.Pharmacology research & perspectives · 2022Review
- Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.Frontiers in pharmacology · 2022Review
- Risk of drug-induced cardiac arrhythmia during COVID-19 therapeutic treatment.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2021Review
- Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments.International journal of environmental research and public health · 2021Review
- Coronavirus disease 2019 in liver transplant patients: Clinical and therapeutic aspects.World journal of hepatology · 2021Review
- Scoping insight on antiviral drugs against COVID-19.Arabian journal of chemistry · 2021Review
- Statins in COVID-19 Therapy.Life (Basel, Switzerland) · 2021Review
- Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.Pharmacology research & perspectives · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-drug interaction (DDI) is a common clinical problem that has occurred as a result of the concomitant use of multiple drugs. DDI may occur in patients under treatment with medications used for coronavirus disease 2019 (COVID-19; i.e., chloroquine, lopinavir/ritonavir, ribavirin, tocilizumab, and remdesivir) and increase the risk of serious adverse reactions such as QT-prolongation, retinopathy, increased risk of infection, and hepatotoxicity. This review focuses on summarizing DDIs for candidate medications used for COVID-19 in order to minimize the adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.